Fig. 2: Kaplan-Meier estimates of the cumulative incidence of six outcomes. | Nature Communications

Fig. 2: Kaplan-Meier estimates of the cumulative incidence of six outcomes.

From: Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China

Fig. 2

Kaplan-Meier estimates of the cumulative incidence of ART switch, LTFU, CD4 improvement, all-cause mortality, AIDS-related mortality, and non-AIDS related mortality. ART antiretroviral therapy, LTFU loss to follow-up, CD4 improvement= transition of people living with HIV from CD4 < 500 cells/μL to CD4 > 500 cells/μL, NVP nevirapine, EFV efavirenz, DTG dolutegravir, LPV lopinavir, Others= darunavir, raltegravie, elvitegravir and rilpivirine. Log-rank test, 2-sided no adjustment for multiple comparisons.

Back to article page